Premium
Ectopic production of 1,25‐dihydroxyvitamin D by B‐cell lymphoma as a cause of hypercalcemia
Author(s) -
Mudde Aart H.,
Berg Henk Van Den,
Boshuis Peter G.,
Breedveld Ferdinand C.,
Markusse Harry M.,
Kluin Phillip M.,
Bijvoet Olav L. M.,
Papapoulos Socrates E.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870501)59:9<1543::aid-cncr2820590902>3.0.co;2-l
Subject(s) - medicine , lymphoma , in vitro , receptor , calcitriol , rheumatoid arthritis , endocrinology , lymph node , vitamin d and neurology , biochemistry , chemistry
A patient with long‐standing rheumatoid arthritis developed hypercalcemia (3.13 mmol/l) and was subsequently found to have a B‐cell lymphoma (centroblastic type). The hypercalcemia was associated with high circulating concentrations of 1,25‐dihydroxyvitamin D (235 pmol/l) and both abnormalities were corrected with treatment. A lymph node was excised before treatment and was incubated in vitro with either labeled or unlabeled 25‐hydroxyvitamin D 3. After purification of the extract and chromatography on three different HPLC systems, material comigrating with authentic 1,25‐dihydroxyvitamin D 3 was identified. This was shown to bind to a specific chick intestinal cytosol receptor and to dilute in parallel with synthetic 1,25‐dihydroxyvitamin D 3 in the receptor binding assay. In conclusion, hypercalcemia in malignant B‐cell lymphoma can be due to extrarenal production of 1,25‐dihydroxyvitamin D by lymphomatous tissue.